Explore the latest in pancreatic cancer, including advances in understanding the epidemiology, diagnosis, management, and prevention of the disease.
This Medical News article examines how studying the characteristics of long-term pancreatic cancer survivors might improve treatment and boost survival for others who have the disease
This case series examines data from 2003 to 2018 regarding patients who underwent aggressive resection operative treatment for locally advanced pancreatic neuroendocrine tumors and their outcomes in terms of disease recurrence, quality of life, and overall 5-year survival.
This cohort study uses data from an existing cohort of patients undergoing resection of pancreatic cancer to assess the overall survival of patients treated with neoadjuvant FOLFIRINOX after surgery for pancreatic ductal adenocarcinoma.
This cohort study examines multiyear self-reported demographic, lifestyle choice, and medical history data to track weight changes, disease diagnoses, health outcomes, and other factors associated with pancreatic cancer risk among participants in 2 long-term national surveys.
A man in his 30s presented with a 3-month history of fourth finger right hand articular heat, pain, redness, and swelling, which developed into widespread arthritis accompanied by ill-defined skin nodules. What is your diagnosis?
This article summarizes “Diagnosis and Management of Pancreatic Cancer in Adults: A Summary of Guidelines From the UK National Institute for Health and Care Excellence,” which is aimed at improving outcomes in pancreatic cancer.
This case series evaluates survival and radiographic and serologic measures of responses associated with administration of FOLFIRINOX or gemcitabine plus nab-paclitaxel as first-line chemotherapy in patients with previously untreated localized pancreatic ductal adenocarcinoma.
This Viewpoint advocates for increased use of neoadjuvant therapy in the treatment of localized pancreatic adenocarcinoma.
This cohort study compares the cancer spectrum and frequencies between male BRCA1 and BRCA2 pathogenic variant carriers.
This cohort study assesses the association of elevation in glycated hemoglobin level with the risk of pancreatic cancer.
A 64-year-old woman with borderline resectable pancreatic adenocarcinoma and a history of hormone receptor–positive left-sided breast cancer had several hypodense lesions in the apex of her heart on chest computed tomography and several discrete, partially mobile frondlike masses originating from her cardiac apex on transthoracic echocardiography. What is your diagnosis?
In this narrative medicine essay, an emergency medicine physician recalls an encounter early in her career when she was asked by parents to make a recommendation regarding ending life support for a young child, reflects on the way practice has changed from physician-centric to patient-involved decision-making, and discusses how her husband’s pancreatic cancer diagnosis brought up a different perspective.
This narrative review discusses the key studies that have established the frequency and types of germline mutations in pancreatic ductal adenocarcinoma and implications for family members, strategies for genetic counseling, and treatment options for individuals with known germline mutations.
This proof-of-concept cohort study evaluates whether surgeon experience with related procedures was associated with better outcomes for pancreaticoduodenectomy compared with procedure-specific experience alone.
This cohort study examines the association of disease progression and health-related quality of life among adult patients with breast, lung, pancreatic, or colorectal cancer.
This cohort study uses the National Cancer Database to examine the level of survival disparity between black and white patients in a modern cohort with pancreatic ductal adenocarcinoma and whether treatment inequity is associated with such a disparity.
This open-label, single-arm, pilot, phase 1b/2 clinical trial assesses outcomes following treatment with nab-paclitaxel plus gemcitabine plus the platinum-based cisplatin for patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: